Corcept医疗 CORT 深 沪
已收盘 01-09 16:00:00 美东时间
37.50
+0.970
+2.66%
华盛通- 最 高37.70
- 今 开36.95
- 成交量 161.32万股
- 最 低 36.20
- 昨 收 36.53
- 总市值 39.38亿
- 52周最高 117.33
- 市盈率 静 30.46
- 换手率 1.54%
- 52周最低 32.9906
- 委 比 -91.77%
- 总股本 1.05亿
- 历史最高 117.33
- 量 比 0.41
- 振 幅 4.11%
- 历史最低 1.27
- 每 手 1
- 风险率 10.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 杰富瑞上调百度目标价从159美元升至181美元；花旗下调京东目标价从44美元下调至37美元
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从47美元升至48美元；BTIG：维持Hudson Pacific Properties"买入"评级，目标价从4.75美元升至26美元
01-05 13:52
美股周涨跌榜 | Sable Offshore涨超37%，获重启加州管道的批准；百度涨超20%
Sable Offshore涨超37%，获重启加州管道的批准；Ondas Holdings涨近30%，获1000万美元新自主系统订单；百度涨超20%，拟分拆昆仑芯于港交所上市>>
01-04 10:38
Corcept sinks as FDA rejects hormonal disorder therapy
Corcept Therapeutics (CORT) fell ~35% in the premarket on Wednesday after the U.S. Food and Drug Administration (FDA) declined to approve its hormonal disorder therapy relacorilant, citing inadequate ...
2025-12-31 21:38
The FDA Has Issued A Complete Response Letter Regarding Corcept Therapeutics' New Drug Application For Relacorilant For Hypertension Secondary To Hypercortisolism
While the FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint and that data from the company's GRADIENT trial provided confirmatory evidence, the Agency concluded it could not arrive at a
2025-12-31 21:02
Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?
Are There Red Flags in the Trial Results? Introduction: Corcept Therapeutics' (...
2025-12-23 00:41
Top picks for 2026 from top-performing funds - Barron's
In a year where beating the market has proven challenging, a select group of stock fund managers have found winning strategies. They shared where they see opportunities ahead with Barron's. With the S...
2025-12-22 02:46
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
UBS Initiates Coverage On Corcept Therapeutics with Neutral Rating, Announces Price Target of $95
UBS analyst Ashwani Verma initiates coverage on Corcept Therapeutics (NASDAQ:CORT) with a Neutral rating and announces Price Target of $95.
2025-12-16 21:39
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $145 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $145 price target.
2025-11-25 20:04
